Literature DB >> 7128667

Pharmacokinetic and pharmacodynamic studies of oral clonidine in normotensive subjects.

S N Anavekar, B Jarrott, M Toscano, W J Louis.   

Abstract

The pharmacokinetics of clonidine and its relation to blood pressure response and side effects were studied after single oral doses of 75 micrograms, 150 micrograms and 250 micrograms in normotensive subjects. Following oral administration, the drug was absorbed rapidly after an initial lag time of 19-22 min and peak levels were reached between 2.4 and 2.9 h. Sampling over 48 h was necessary for accurate estimation of pharmacokinetic parameters. Post-peak plasma concentration declined in a monoexponential manner and the half-life of the elimination phase ranged from 9.0 to 15.1 h. Maximum plasma concentration (Cmax) and area under curve (AUC) increased proportionally with increasing doses. Clonidine produced significant reductions in the pulse rate and a dose dependent decrease in blood pressure. Clonidine (150 micrograms) also produced significant reductions in plasma catecholamine levels.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7128667     DOI: 10.1007/bf01061368

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  11 in total

1.  Clinical pharmacology and pharmacokinetics of clonidine.

Authors:  C T Dollery; D S Davies; G H Draffan; H J Dargie; C R Dean; J L Reid; R A Clare; S Murray
Journal:  Clin Pharmacol Ther       Date:  1976-01       Impact factor: 6.875

2.  Simultaneous radioenzymatic determination of plasma and tissue adrenaline, noradrenaline and dopamine within the femtomole range.

Authors:  M Da Prada
Journal:  Life Sci       Date:  1976-10-15       Impact factor: 5.037

3.  A functional basis for classification of alpha-adrenergic receptors.

Authors:  S Berthelsen; W A Pettinger
Journal:  Life Sci       Date:  1977-09-01       Impact factor: 5.037

4.  Pharmacokinetics and concentration-effect relationships of intervenous and oral clonidine.

Authors:  D S Davies; A M Wing; J L Reid; D M Neill; P Tippett; C T Dollery
Journal:  Clin Pharmacol Ther       Date:  1977-05       Impact factor: 6.875

5.  Properties of catapres, a new hypotensive drug: a preliminary report.

Authors:  J Ng; D D McGrgor; K M Taylor; H Smirk
Journal:  N Z Med J       Date:  1967-12

6.  AUTOMOD: a polyalgorithm for an integrated analysis of linear pharmacokinetic models.

Authors:  R Gomeni; C Gomeni
Journal:  Comput Biol Med       Date:  1979       Impact factor: 4.589

7.  Suppression of plasma catecholamines and flushing by clonidine in man.

Authors:  S A Metz; J B Halter; D Porte; R P Robertson
Journal:  J Clin Endocrinol Metab       Date:  1978-01       Impact factor: 5.958

8.  The physiological disposition of 2(2,6-dichloroanilino)-2-imidazoline (St-155).

Authors:  A K Cho; S H Curry
Journal:  Biochem Pharmacol       Date:  1969-02       Impact factor: 5.858

9.  Pharmacokinetics of clonidine and its relation to the hypotensive effect in patients.

Authors:  M Frisk-Holmberg; P O Edlund; L Paalzow
Journal:  Br J Clin Pharmacol       Date:  1978-09       Impact factor: 4.335

10.  Disposition of clonidine in rats as determined by radioimmunoassay.

Authors:  B Jarrott; S Spector
Journal:  J Pharmacol Exp Ther       Date:  1978-10       Impact factor: 4.030

View more
  11 in total

1.  MDMA enhances "mind reading" of positive emotions and impairs "mind reading" of negative emotions.

Authors:  Cédric M Hysek; Gregor Domes; Matthias E Liechti
Journal:  Psychopharmacology (Berl)       Date:  2012-01-27       Impact factor: 4.530

2.  Effects of MDMA alone and after pretreatment with reboxetine, duloxetine, clonidine, carvedilol, and doxazosin on pupillary light reflex.

Authors:  Cédric M Hysek; Matthias E Liechti
Journal:  Psychopharmacology (Berl)       Date:  2012-06-15       Impact factor: 4.530

Review 3.  Is clonidine an effective smoking cessation therapy?

Authors:  S G Gourlay; N L Benowitz
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

4.  Clonidine reduces hypersensitivity and alters the balance of pro- and anti-inflammatory leukocytes after local injection at the site of inflammatory neuritis.

Authors:  Alfonso Romero-Sandoval; James C Eisenach
Journal:  Brain Behav Immun       Date:  2006-10-31       Impact factor: 7.217

5.  Pharmacokinetics and pharmacodynamics of transdermally administered clonidine.

Authors:  D Arndts; K Arndts
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

6.  A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women.

Authors:  Alice Ban Ke; Srikanth C Nallani; Ping Zhao; Amin Rostami-Hodjegan; Nina Isoherranen; Jashvant D Unadkat
Journal:  Drug Metab Dispos       Date:  2013-01-25       Impact factor: 3.922

Review 7.  Clinical pharmacokinetics of clonidine.

Authors:  D T Lowenthal; K M Matzek; T R MacGregor
Journal:  Clin Pharmacokinet       Date:  1988-05       Impact factor: 6.447

8.  The protocol of the Oslo Study of Clonidine in Elderly Patients with Delirium; LUCID: a randomised placebo-controlled trial.

Authors:  Bjørn Erik Neerland; Karen Roksund Hov; Vegard Bruun Wyller; Eirik Qvigstad; Eva Skovlund; Alasdair M J MacLullich; Torgeir Bruun Wyller
Journal:  BMC Geriatr       Date:  2015-02-10       Impact factor: 3.921

9.  Effects of low-dose clonidine on cardiovascular and autonomic variables in adolescents with chronic fatigue: a randomized controlled trial.

Authors:  Even Fagermoen; Dag Sulheim; Anette Winger; Anders M Andersen; Johannes Gjerstad; Kristin Godang; Peter C Rowe; J Philip Saul; Eva Skovlund; Vegard Bruun Wyller
Journal:  BMC Pediatr       Date:  2015-09-10       Impact factor: 2.125

10.  The use of clonidine in elderly patients with delirium; pharmacokinetics and hemodynamic responses.

Authors:  Karen Roksund Hov; Bjørn Erik Neerland; Anders Mikal Andersen; Øystein Undseth; Vegard Bruun Wyller; Alasdair M J MacLullich; Eva Skovlund; Eirik Qvigstad; Torgeir Bruun Wyller
Journal:  BMC Pharmacol Toxicol       Date:  2018-06-08       Impact factor: 2.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.